ISHI Islet Holdings Inc (CE)

Islet Holdings, Inc. (PINKSHEETS: ISHI) -- Islet Holdings, Inc. ("the Company"), announced today that it has completed steps necessary for the acquisition of Isletech, Inc., a privately-held corporation which has successfully acquired certain intellectual property in the medical field of treating type 1 diabetes.

The Company, through its operating subsidiary Isletech, Inc., is a biotech company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with conditions requiring cell-based replacement treatments, with a focus on type 1, or insulin-dependent diabetes. The Company intends to continue research and development efforts and, ultimately, to introduce products to the market.

The Company is currently working on securing contracts with strategic medical experts and businesses partners, as well as secure financing for operations.

Release Note: Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. The realization of any or all of these expectations is subject to a number of risks and uncertainties and it is possible that the assumptions made by management may not materialize.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Mercantile Ascendency 214-670-2450